Anatomically designed mask will assist millions of Americans suffering from chronic lung disease

PLATTSBURGH, NY (June 5, 2019) – Monaghan Medical Corporation (MMC) today introduced new product enhancements to continue their mission to ensure device quality for patients. Close to …

Two new publications build on previous evidence that not all devices are equally effective in delivering asthma control.

PLATTSBURGH, N.Y., Jan. 31, 2018 — A recent article in Pulmonary Pharmacology and Physiology¹ provides in vitro evidence that the AEROCHAMBER …

Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system.  A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the AEROBIKA® oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1 …

SYRACUSE, NY, 21 February, 2017 – Monaghan Medical Corporation (MMC) today announced the publication of a study in Pulmonary Therapy showing treatment with the Aerobika^® device can significantly reduce the recurrence of exacerbations of COPD in the crucial 30-day …

SYRACUSE, NY, January 12, 2017 – Monaghan Medical Corporation (MMC) today announced that the findings of a study published in the most recent issue of Academic Radiology shows that patients with non-cystic fibrosis (CF) bronchiectasis responded favorably to airway maintenance …

Real-world study presented at CHEST 2016 Annual Meeting in Los Angeles

SYRACUSE, NY, October 27, 2016 – Monaghan Medical Corporation (MMC) today announced that a new study presented to the American College of Chest Physicians (CHEST) shows MMC’s Aerobika® device …